Follow The Filings

BOLT Bolt Biotherapeutics Inc.

Health Care, filed as BOLT BIOTHERAPEUTICS INC (COM NEW), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by BOLT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BOLT insider trades
  • $5,594 bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Sarah Nemec Senior VP, Finance and PAO
    Buy
    $1,973 509 shares at $3.88 +36% to stake
    Traded Jun 5 Filed Sep 21
    ↗
  2. William P. Quinn CEO
    Buy
    $2,469 637 shares at $3.88 +28% to stake
    Traded Jun 5 Filed Sep 21
    ↗
  3. William P. Quinn CEO
    Buy
    $576 125 shares at $4.61 +5.7% to stake
    Traded Dec 5, 2025 Filed Feb 4
    ↗
  4. Sarah Nemec Senior VP, Finance and PAO
    Buy
    $687 125 shares at $5.49 +15% to stake
    Traded Jun 6, 2025 Filed Oct 24, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 sales to cover taxes and 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 1.01,1.02,2.01,3.02,5.02,5.03,7.01,8.01,9.01 Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 9 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $7.88M $7.69M $7.7M
Net income -$69.2M -$63.12M -$33.38M
Net margin * -878.6% -820.8% -433.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $105.71M $50.81M $30.26M
Total non-current assets * $54.08M $48.82M $26.49M
Total assets $159.78M $99.63M $56.75M
Total current liabilities $20.46M $15.86M $8.44M
Total non-current liabilities * $26.59M $26.58M $21.81M
Total equity $112.74M $57.2M $26.5M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$69.52M -$61.29M -$39.85M
Cash from investing $71.04M $57.58M $44.3M
Cash from financing $253,000 $108,000 $19,000
Net change in cash $1.77M -$3.6M $4.47M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf